TY - JOUR
T1 - Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer
AU - De Ruysscher, Dirk
AU - Dehing, Cary
AU - Yu, Shipeng
AU - Wanders, Rinus
AU - Öllers, Michel
AU - Dingemans, Anne Marie C.
AU - Bootsma, Gerben
AU - Hochstenbag, Monique
AU - Geraedts, Wiel
AU - Pitz, Cordula
AU - Simons, Jean
AU - Boersma, Liesbeth
AU - Borger, Jacques
AU - Dekker, Andre
AU - Lambin, Philippe
PY - 2009/6
Y1 - 2009/6
N2 - Purpose: To determine what the influence is of dyspnea (CTCAE3.0) before high-dose radiotherapy (RT) on the incidence and severity of subsequent lung toxicity in patients with non-small cell lung cancer (NSCLC). Methods: In 197 patients with stage I-III NSCLC maximal dyspnea scores (CTCAE3.0) were obtained prospectively at three time periods: before RT, the first 6 months post-RT and 6-9 months post-RT. Only patients who were clinically progression-free 12 months or more after RT were included, thus minimizing dyspnea due to tumor progression. Time-trends of dyspnea as a function of baseline dyspnea were investigated and correlated with gender, age, chemotherapy, mean lung dose (MLD), lung function parameters (FeV1 and DLCO), stage, PTV dose, overall treatment time and smoking habits. Results: The proportion developing less, the same or more dyspnea 6-9 months post-treatment according to their baseline dyspnea scores was: Grade 0: none, 82.9%, 17.1%; Grade 1: 21.2%, 51.9%, 26.9%; Grade 2: 27.3%, 54.5%, 18.2%, respectively. Only age was associated with increased dyspnea after RT. Conclusions: Patients with dyspnea before therapy have a realistic chance to improve after high-dose radiotherapy. Reporting only dyspnea at one time-point post-RT is insufficient to determine radiation-induced dyspnea.
AB - Purpose: To determine what the influence is of dyspnea (CTCAE3.0) before high-dose radiotherapy (RT) on the incidence and severity of subsequent lung toxicity in patients with non-small cell lung cancer (NSCLC). Methods: In 197 patients with stage I-III NSCLC maximal dyspnea scores (CTCAE3.0) were obtained prospectively at three time periods: before RT, the first 6 months post-RT and 6-9 months post-RT. Only patients who were clinically progression-free 12 months or more after RT were included, thus minimizing dyspnea due to tumor progression. Time-trends of dyspnea as a function of baseline dyspnea were investigated and correlated with gender, age, chemotherapy, mean lung dose (MLD), lung function parameters (FeV1 and DLCO), stage, PTV dose, overall treatment time and smoking habits. Results: The proportion developing less, the same or more dyspnea 6-9 months post-treatment according to their baseline dyspnea scores was: Grade 0: none, 82.9%, 17.1%; Grade 1: 21.2%, 51.9%, 26.9%; Grade 2: 27.3%, 54.5%, 18.2%, respectively. Only age was associated with increased dyspnea after RT. Conclusions: Patients with dyspnea before therapy have a realistic chance to improve after high-dose radiotherapy. Reporting only dyspnea at one time-point post-RT is insufficient to determine radiation-induced dyspnea.
UR - http://www.scopus.com/inward/record.url?scp=65649089303&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2008.10.006
DO - 10.1016/j.radonc.2008.10.006
M3 - Article
C2 - 19012981
AN - SCOPUS:65649089303
SN - 0167-8140
VL - 91
SP - 353
EP - 359
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -
